21 一月 2015

Sale of Redvax to Pfizer

VISCHER represents the sellers of Redvax GmbH, in Schlieren in its sale to Pfizer. Redvax is a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. Redvax develops a preclinical human cytomegalovirus (CMV) vaccine candidate, a herpes virus. A vaccine could prevent a CMV infection during pregnancy and of passing the infection on to the unborn child. The VISCHER-team is led by Matthias Staehelin (Corporate) und Nadia Tarolli (Tax) with Dania Salvisberg-Schneider, Mathias Kuster, Sara Ianni (all Corporate) and Melanie Knüsel, Meral Korkmaz and Isabelle Stebler (all Tax).

分享文章至:

包含的服务:

与我们的作者取得联系,受益于他们的专业知识:

partner-Matthias-0

Matthias Staehelin

matthias.staehelin@vischer.com

+41 58 211 33 53

partner-Nadia-1

Nadia Tarolli Schmidt

nadia.tarolli@vischer.com

+41 58 211 33 54

我们的
新闻通讯

Sale of Redvax to Pfizer